Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Sales (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Return on Sales data on record, last reported at 1.02% in Q4 2025.

  • For Q4 2025, Return on Sales fell 85.0% year-over-year to 1.02%; the TTM value through Dec 2025 reached 0.12%, up 13.0%, while the annual FY2025 figure was 0.12%, 13.0% up from the prior year.
  • Return on Sales reached 1.02% in Q4 2025 per APLS's latest filing, down from 0.47% in the prior quarter.
  • Across five years, Return on Sales topped out at 17.77% in Q4 2022 and bottomed at 351.83% in Q2 2021.
  • Average Return on Sales over 5 years is 20.12%, with a median of 0.79% recorded in 2025.
  • Peak YoY movement for Return on Sales: tumbled -2691bps in 2021, then soared 34227bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 4.7% in 2021, then surged by 278bps to 17.77% in 2022, then crashed by -102bps to 0.27% in 2023, then soared by 38bps to 0.17% in 2024, then plummeted by -496bps to 1.02% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 1.02% in Q4 2025, 0.47% in Q3 2025, and 0.24% in Q2 2025.